Last reviewed · How we verify

NICARDIPINE HYDROCHLORIDE

FDA-approved approved Small molecule Quality 53/100

Nicardipine blocks calcium ion influx into vascular smooth muscle, causing relaxation with minimal effect on cardiac muscle.

Nicardipine Hydrochloride is a marketed drug primarily indicated for chronic stable angina, with a key composition patent expiring in 2028. Its mechanism of action, which selectively blocks calcium ion influx into vascular smooth muscle, provides a significant therapeutic benefit with minimal impact on cardiac muscle, distinguishing it in the treatment landscape. The primary risk is the potential increase in generic competition following the patent expiry in 2028.

At a glance

Generic nameNICARDIPINE HYDROCHLORIDE
Drug classCalcium channel blocker
TargetCalcium ion channels
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved
First approval1988

Mechanism of action

Nicardipine works by blocking the entry of calcium ions into cells, particularly targeting vascular smooth muscle. This leads to relaxation of blood vessels, which can help reduce blood pressure and improve blood flow, while having minimal impact on heart muscle function.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Patents

PatentExpiryType
84555242027-04-18Method of Use
76592912027-04-18Method of Use
115477582027-04-18Method of Use
93645642027-12-26Formulation
76121022027-12-26Formulation
107586162027-04-18Formulation

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: